{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/ew-stock-analysis/",
 "dataUrl": "https://clearank.com/stock/ew-stock-analysis/data.json",
 "title": "Edwards Lifesciences Corporation (EW) Stock Forecast (2026)",
 "description": "Is Edwards Lifesciences (EW) a Buy or Sell today? Get the AI trade setup, key support levels, valuation and risk analysis. Updated daily.",
 "headline": "Edwards Lifesciences Corporation (EW)",
 "published": "2026-09-04T09:24:46+00:00",
 "modified": "2026-09-12T09:45:59.176+00:00",
 "generated": "2026-09-13T01:35:24.984Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "EW",
  "name": "Edwards Lifesciences Corporation",
  "type": "Common Stock",
  "exchange": "NYSE",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Medical Devices",
  "country": "United States",
  "website": "https://www.edwards.com"
 },
 "quote": {
  "price": 84.37,
  "previousClose": 86.77,
  "change": -2.4,
  "changePercent": -2.77,
  "open": 87.51,
  "high": 87.76,
  "low": 83.81,
  "volume": 3795200,
  "averageVolume": 2813180,
  "marketCap": 48580246000,
  "fiftyTwoWeekHigh": 96.29,
  "fiftyTwoWeekLow": 72.3,
  "marketOpen": false,
  "asOf": "2026-09-12T09:45:58.000Z"
 },
 "statistics": {
  "pe": 51.604794,
  "eps": 1.67,
  "dividendYield": 0,
  "beta": 0.852,
  "priceToSales": 7.6198034,
  "priceToBook": 4.67988,
  "revenueTtm": 6512300032,
  "grossMargin": 0.7746122917863297,
  "returnOnEquity": 0.09175
 },
 "technicals": {
  "rsi": 24.81,
  "macd": -0.79,
  "sma50": 89.23,
  "sma200": 84.97,
  "rsiSignal": "Oversold",
  "trend": "Bullish",
  "pricePosition": "Bearish",
  "macdSignal": "Bearish",
  "rating": "Bearish"
 },
 "analysis": {
  "rating": "Sell",
  "score": 21,
  "consensus": "Sell",
  "fairValue": 84.37,
  "analystTarget": 101.5,
  "analystCount": 29,
  "wallStreetConsensus": "Buy",
  "generatedAt": "2026-09-12T09:45:58.000Z",
  "priceAtAnalysis": 84.37,
  "volatility": {
   "daily": 1.41,
   "risk": "standard"
  }
 },
 "tradePlan": {
  "bias": "Bearish",
  "conservativeEntry": 86.06,
  "aggressiveEntry": 84.37,
  "stopLoss": 92.75,
  "stopLossPercent": 7.78,
  "targets": [
   81.75,
   77.45,
   73.15
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 59.45,
    "base": 90.83,
    "upside90th": 138.76
   },
   {
    "year": 2028,
    "downside10th": 53.7,
    "base": 97.79,
    "upside90th": 178.06
   },
   {
    "year": 2029,
    "downside10th": 50.53,
    "base": 105.27,
    "upside90th": 219.33
   },
   {
    "year": 2030,
    "downside10th": 48.56,
    "base": 113.34,
    "upside90th": 264.52
   },
   {
    "year": 2031,
    "downside10th": 47.3,
    "base": 122.01,
    "upside90th": 314.74
   },
   {
    "year": 2032,
    "downside10th": 46.52,
    "base": 131.36,
    "upside90th": 370.92
   },
   {
    "year": 2033,
    "downside10th": 46.09,
    "base": 141.42,
    "upside90th": 433.95
   },
   {
    "year": 2034,
    "downside10th": 45.92,
    "base": 152.25,
    "upside90th": 504.78
   },
   {
    "year": 2035,
    "downside10th": 45.97,
    "base": 163.9,
    "upside90th": 584.42
   },
   {
    "year": 2036,
    "downside10th": 46.2,
    "base": 176.46,
    "upside90th": 673.97
   }
  ]
 },
 "faqCount": 7,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "EW Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$87.51",
    "Day Range": "$83.81 to $87.76",
    "Prev Close": "$86.77",
    "Volume": "3.80M",
    "52-Week Range": "$72.30 to $96.29",
    "Market Cap": "$48.58B"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis Trading at a significant premium to sector peers (+62%), suggesting market expectations for superior growth or market position."
   ]
  },
  {
   "id": "analysis",
   "title": "EW Analysis",
   "text": [
    "Edwards Lifesciences Corporation's stock is currently trading below its 50-day SMA of $89.23 and its 200-day SMA of $84.97, indicating a bearish trend. The RSI is at an oversold level of 24.81, suggesting a potential for a short-term bounce. MACD is at -0.786864842418538, also indicating bearish momentum. The nearest support level is the current price at $84.37, with resistance found at the 200-day SMA of $84.97 and the 50-day SMA of $89.23. Volume has been above average recently, with the latest volume at 3.79 million compared to an average of 2.81 million, suggesting increased investor interest, though currently in a downtrend.",
    "If Edwards Lifesciences reports Q3 2026 EPS significantly above the $0.78 actual from Q2 2026 and the analyst estimate of $0.74, it could signal renewed fundamental strength and drive the stock higher.",
    "Positive outcomes from ongoing clinical trials for new medical devices could significantly boost investor confidence and provide a strong catalyst for share price appreciation.",
    "Sustained or increased insider selling activity, particularly by company officers, could signal a lack of confidence in future performance and exert downward pressure on the stock price.",
    "If the market continues to de-rate high-multiple stocks, EW's P/E ratio of 51.60 could face significant compression, leading to a price decline even if revenue growth remains steady.",
    "The base case for Edwards Lifesciences Corporation over the next 6-12 months suggests continued pressure given the current technical setup and valuation concerns. While revenue growth is projected to remain strong at around 10-11% annually, the stock's P/E ratio of 51.60 remains a significant overhang compared to the sector median of 31.9. The oversold RSI at 24.81 may provide some short-term support, but a sustained move higher would require a clear catalyst to justify the premium valuation and overcome the moderate insider selling. Upside catalysts could include stronger-than-expected earnings beats that significantly surpass analyst estimates, positive developments in new product pipelines, or a broader market rotation into healthcare value stocks. Conversely, downside risks include continued insider selling, a failure to meet revenue growth expectations, increased competition in the medical device sector, or a general market downturn that disproportionately affects high-valuation stocks. A breach below the $84.37 current price could signal further declines towards the lower end of the analyst price targets."
   ],
   "lists": {
    "ProTips": [
     "Monitor upcoming earnings reports closely for any signs of acceleration in revenue growth or improved profitability to justify the current valuation.",
     "Given the oversold RSI, consider waiting for confirmation of a technical bounce before initiating new positions.",
     "The moderate insider selling warrants attention; track future insider transactions for any shifts in sentiment."
    ]
   },
   "catalysts": [
    {
     "type": "Bullish",
     "title": "Strong Q3 2026 Earnings Beat",
     "text": "If Edwards Lifesciences reports Q3 2026 EPS significantly above the $0.78 actual from Q2 2026 and the analyst estimate of $0.74, it could signal renewed fundamental strength and drive the stock higher.",
     "source": "Analyst Estimates"
    },
    {
     "type": "Bullish",
     "title": "Positive Clinical Trial Results",
     "text": "Positive outcomes from ongoing clinical trials for new medical devices could significantly boost investor confidence and provide a strong catalyst for share price appreciation.",
     "source": "Company Pipeline"
    },
    {
     "type": "Bearish",
     "title": "Continued Insider Selling",
     "text": "Sustained or increased insider selling activity, particularly by company officers, could signal a lack of confidence in future performance and exert downward pressure on the stock price.",
     "source": "Insider Transactions"
    },
    {
     "type": "Bearish",
     "title": "Valuation Compression",
     "text": "If the market continues to de-rate high-multiple stocks, EW's P/E ratio of 51.60 could face significant compression, leading to a price decline even if revenue growth remains steady.",
     "source": "Market Trends"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "Edwards Lifesciences Corporation exhibits a high P/E ratio of 51.60, considerably above the healthcare sector median of 31.9, indicating a potentially overvalued stock based on current earnings. While the company demonstrates strong revenue growth, with current year estimates at 11.00% and next year at 10.00%, its earnings per share (EPS) of $1.67 does not fully justify the current valuation. The company's return on equity (ROE) is 6.9%, which is below the sector median of 6.9%, further questioning the efficiency of its operations relative to its peers. The lack of significant insider selling, coupled with moderate insider selling totaling $34.6 million, adds a layer of concern to the fundamental picture.",
    "Edwards Lifesciences Corporation most recently reported Q2 2026 earnings on July 23, 2026, with an EPS of $0.78, beating the estimate of $0.74 by 5.41%, though the stock price declined by 1.42%. Prior to this, Q1 2026 earnings on April 23, 2026, showed an EPS of $0.78, beating estimates by 6.85% and resulting in a 5.56% price increase. The company missed estimates in Q4 2025 and Q3 2025, indicating an inconsistent earnings performance over the past year.",
    "Edwards Lifesciences Corporation faces significant risks including its elevated valuation, with a P/E ratio of 51.60 compared to the sector median of 31.9. The stock is currently trading below key technical indicators, including the 50-day and 200-day SMAs, and exhibits oversold RSI conditions, suggesting potential for further downside. Additionally, moderate insider selling totaling $34.6 million indicates a lack of strong conviction from management at current price levels."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "48.58B"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "51.60"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "1.67"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "0.00%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "96.29"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "72.30"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Bearish RSI Oversold SMA Cross Bullish Price vs SMA Bearish MACD Bearish Golden Cross in effect with the 50-day SMA ($89.23) above the 200-day SMA ($84.97), price is trading below the 50-day SMA, RSI at 24.8 suggests oversold conditions; potential bounce setup."
   ],
   "facts": {
    "RSI": "Oversold",
    "SMA Cross": "Bullish",
    "Price vs SMA": "Bearish",
    "MACD": "Bearish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "24.81"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "-0.79"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "89.23"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "84.97"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.24",
    "Correlation with Nasdaq 100 (QQQ)": "+0.22",
    "Correlation with Bitcoin (BTC)": "+0.08",
    "Correlation with Gold (XAU)": "+0.02"
   }
  },
  {
   "id": "trade-plans",
   "title": "EW Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Lower risk, wait for rally",
    "Higher risk, chasing the move",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (24.8) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$81.75",
    "TARGET 2": "$77.45",
    "TARGET 3": "$73.15",
    "STOP LOSS": "$92.75"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "1.41%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in EW in September 2016 would be worth about $21,779 today, compared with about $35,328 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in EW today could grow to about $20,915 by 2036 in the base case, with a bull case near $79,882 and a bear case around $5,476. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "EW Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $113 for EW by 2030 in the base case, from $84.37 today (1.3x over 4 years). The downside path ends near $48.56. These are outcomes of a Monte Carlo simulation run on EW's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using EW's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "EW simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$59.45",
        "$90.83",
        "$139"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$53.70",
        "$97.79",
        "$178"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$50.53",
        "$105",
        "$219"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$48.56",
        "$113",
        "$265"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$47.30",
        "$122",
        "$315"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$46.52",
        "$131",
        "$371"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$46.09",
        "$141",
        "$434"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$45.92",
        "$152",
        "$505"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$45.97",
        "$164",
        "$584"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$46.20",
        "$176",
        "$674"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "ILMN Illumina Inc. NASDAQ $206.45 +2.57%",
     "url": "https://clearank.com/stock/ilmn-stock-analysis/"
    },
    {
     "text": "HIMS Hims & Hers Health, Inc. NYSE $27.51 +0.26%",
     "url": "https://clearank.com/stock/hims-hers-health-hims/"
    },
    {
     "text": "MOH Molina Healthcare Inc. NYSE $204.23 +1.97%",
     "url": "https://clearank.com/stock/moh-stock-analysis/"
    },
    {
     "text": "PFE Pfizer Inc. NYSE $27.72 +0.25%",
     "url": "https://clearank.com/stock/pfizer-pfe/"
    },
    {
     "text": "MRK Merck & Co., Inc. NYSE $143.93 -0.54%",
     "url": "https://clearank.com/stock/merck-mrk/"
    },
    {
     "text": "VRTX Vertex Pharmaceuticals Incorporated NASDAQ $515.44 +0.17%",
     "url": "https://clearank.com/stock/vertex-vrtx/"
    },
    {
     "text": "DHR Danaher Corp. NYSE $200.14 -0.19%",
     "url": "https://clearank.com/stock/dhr-stock-analysis/"
    },
    {
     "text": "ELV Elevance Health, Inc. NYSE $418.72 +0.52%",
     "url": "https://clearank.com/stock/elv-stock-analysis/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Popular Comparisons",
   "links": [
    {
     "text": "SCHD vs VYM Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/schd-vs-vym/"
    },
    {
     "text": "AMD vs ARM Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/amd-vs-arm/"
    },
    {
     "text": "COP vs OXY Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/cop-vs-oxy/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "EW Insider Trading Analysis",
   "facts": {
    "Bought": "None",
    "Sold": "$34.0M",
    "Insiders": "18",
    "Avg Transaction": "$641.0K"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in EW",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "May 10, 2023",
       "cells": [
        "ULLEM SCOTT B Chief Financial Officer",
        "Sell",
        "80.7K",
        "$7.1M"
       ]
      },
      {
       "label": "May 9, 2023",
       "cells": [
        "SZYMAN CATHERINE M Officer",
        "Sell",
        "75.6K",
        "$6.7M"
       ]
      },
      {
       "label": "Jan 15, 2021",
       "cells": [
        "MUSSALLEM MICHAEL A Chief Executive Officer",
        "Sell",
        "68.6K",
        "$6.0M"
       ]
      },
      {
       "label": "Nov 17, 2020",
       "cells": [
        "MUSSALLEM MICHAEL A Chief Executive Officer",
        "Sell",
        "68.6K",
        "$5.8M"
       ]
      },
      {
       "label": "Dec 14, 2020",
       "cells": [
        "MUSSALLEM MICHAEL A Chief Executive Officer",
        "Sell",
        "68.6K",
        "$5.8M"
       ]
      },
      {
       "label": "Apr 8, 2021",
       "cells": [
        "MUSSALLEM MICHAEL A Chief Executive Officer",
        "Sell",
        "68.6K",
        "$5.8M"
       ]
      },
      {
       "label": "Feb 23, 2021",
       "cells": [
        "MUSSALLEM MICHAEL A Chief Executive Officer",
        "Sell",
        "68.6K",
        "$5.8M"
       ]
      },
      {
       "label": "Oct 9, 2020",
       "cells": [
        "MUSSALLEM MICHAEL A Chief Executive Officer",
        "Sell",
        "68.6K",
        "$5.7M"
       ]
      },
      {
       "label": "Mar 9, 2021",
       "cells": [
        "MUSSALLEM MICHAEL A Chief Executive Officer",
        "Sell",
        "68.6K",
        "$5.7M"
       ]
      },
      {
       "label": "Sep 29, 2020",
       "cells": [
        "MUSSALLEM MICHAEL A Chief Executive Officer",
        "Sell",
        "68.6K",
        "$5.4M"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=Edwards+Lifesciences+Corporation&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "Is Edwards Lifesciences Corporation stock a buy right now?",
   "answer": "Edwards Lifesciences Corporation (EW) is currently trading at $84.37. While Wall Street analysts have a 'Buy' consensus and a median price target of $101.50, the stock is below its key moving averages and shows moderate insider selling. The high P/E ratio of 51.60 also suggests a premium valuation."
  },
  {
   "question": "What is the technical outlook for EW stock?",
   "answer": "The technical outlook for EW stock is currently bearish, as it is trading below its 50-day and 200-day moving averages ($89.23 and $84.97). The RSI is in oversold territory at 24.81, which could signal a potential short-term bounce, but the overall trend indicates weakness."
  },
  {
   "question": "What are the key risks facing Edwards Lifesciences Corporation?",
   "answer": "Key risks include its high valuation relative to sector peers, current bearish technical indicators, and moderate insider selling. The company's earnings performance has also been inconsistent over the past year."
  },
  {
   "question": "What is the revenue growth forecast for Edwards Lifesciences Corporation?",
   "answer": "Revenue growth is projected to be strong, with an estimated 11.00% year-over-year increase for the current year, reaching approximately $6.8 billion, and a further 10.00% growth projected for next year, totaling around $7.4 billion."
  },
  {
   "question": "How does EW's valuation compare to its sector averages?",
   "answer": "Edwards Lifesciences Corporation's P/E ratio of 51.60 is significantly higher than the healthcare sector median of 31.9. Its ROE of 6.9% is also at the sector median, suggesting its valuation is not supported by superior operational efficiency compared to peers."
  },
  {
   "question": "What is the consensus among Wall Street analysts for EW stock?",
   "answer": "The consensus among 29 Wall Street analysts is 'Buy', with a score of 72 out of 100. The median price target is $101.50, implying an upside of 20.3% from the current price of $84.37."
  },
  {
   "question": "What does the insider transaction data indicate for EW stock?",
   "answer": "Insider transactions show a 'Net Seller' position, with $34.6 million in total sales and no reported purchases. This 'Moderate Sell Signal' suggests that insiders are reducing their holdings, which can be a cautionary indicator."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "ILMN",
    "name": "Illumina Inc. NASDAQ",
    "price": "$206.45",
    "change": "+2.57%",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "HIMS",
    "name": "Hims & Hers Health, Inc. NYSE",
    "price": "$27.51",
    "change": "+0.26%",
    "url": "https://clearank.com/stock/hims-hers-health-hims/"
   },
   {
    "ticker": "MOH",
    "name": "Molina Healthcare Inc. NYSE",
    "price": "$204.23",
    "change": "+1.97%",
    "url": "https://clearank.com/stock/moh-stock-analysis/"
   },
   {
    "ticker": "PFE",
    "name": "Pfizer Inc. NYSE",
    "price": "$27.72",
    "change": "+0.25%",
    "url": "https://clearank.com/stock/pfizer-pfe/"
   },
   {
    "ticker": "MRK",
    "name": "Merck & Co., Inc. NYSE",
    "price": "$143.93",
    "change": "-0.54%",
    "url": "https://clearank.com/stock/merck-mrk/"
   },
   {
    "ticker": "VRTX",
    "name": "Vertex Pharmaceuticals Incorporated NASDAQ",
    "price": "$515.44",
    "change": "+0.17%",
    "url": "https://clearank.com/stock/vertex-vrtx/"
   },
   {
    "ticker": "DHR",
    "name": "Danaher Corp. NYSE",
    "price": "$200.14",
    "change": "-0.19%",
    "url": "https://clearank.com/stock/dhr-stock-analysis/"
   },
   {
    "ticker": "ELV",
    "name": "Elevance Health, Inc. NYSE",
    "price": "$418.72",
    "change": "+0.52%",
    "url": "https://clearank.com/stock/elv-stock-analysis/"
   }
  ],
  "comparisons": [
   {
    "ticker": "SCHD vs VYM Comparison",
    "name": "",
    "url": "https://clearank.com/compare/schd-vs-vym/"
   },
   {
    "ticker": "AMD vs ARM Comparison",
    "name": "",
    "url": "https://clearank.com/compare/amd-vs-arm/"
   },
   {
    "ticker": "COP vs OXY Comparison",
    "name": "",
    "url": "https://clearank.com/compare/cop-vs-oxy/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "SPG",
    "text": "Simon Property Group Inc.",
    "url": "https://clearank.com/stock/spg-stock-analysis/"
   },
   {
    "ticker": "JCI",
    "text": "Johnson Controls International",
    "url": "https://clearank.com/stock/jci-stock-analysis/"
   },
   {
    "ticker": "BLDR",
    "text": "Builders FirstSource Inc.",
    "url": "https://clearank.com/stock/bldr-stock-analysis/"
   },
   {
    "ticker": "EIS",
    "text": "iShares MSCI Israel ETF",
    "url": "https://clearank.com/etf/eis-etf-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "FPS",
    "text": "↑ 8.97%",
    "url": "https://clearank.com/stock/fps-stock-analysis/"
   },
   {
    "ticker": "HUT",
    "text": "↑ 8.83%",
    "url": "https://clearank.com/stock/hut-stock-analysis/"
   },
   {
    "ticker": "NTAP",
    "text": "↑ 8.54%",
    "url": "https://clearank.com/stock/netapp-ntap/"
   },
   {
    "ticker": "HPQ",
    "text": "↑ 8.40%",
    "url": "https://clearank.com/stock/hpq-stock-analysis/"
   },
   {
    "ticker": "RAY/USD",
    "text": "↓ 8.33%",
    "url": "https://clearank.com/crypto/raydium-ray-usd/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "ABT",
    "text": "Abbott Laboratories",
    "url": "https://clearank.com/stock/abbott-laboratories-abt/"
   },
   {
    "ticker": "BSX",
    "text": "Boston Scientific Corporation",
    "url": "https://clearank.com/stock/boston-scientific-bsx/"
   },
   {
    "ticker": "DXCM",
    "text": "DexCom",
    "url": "https://clearank.com/stock/dxcm-stock-analysis/"
   },
   {
    "ticker": "GEHC",
    "text": "GE HealthCare",
    "url": "https://clearank.com/stock/ge-healthcare-gehc/"
   },
   {
    "ticker": "MDT",
    "text": "Medtronic plc",
    "url": "https://clearank.com/stock/medtronic-mdt/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "url": "https://clearank.com",
     "sameAs": [
      "https://twitter.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank"
     ],
     "email": "info@clearank.com",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "description": "The CleaRank vision is to bring clarity to the online trading industry and protect trader interests. We use our proprietary technology, expert analysis and verified trader insights, to deliver data driven broker evaluations you can trust. Our CLEAR™ Score is our foundation, a transparent, unbiased methodology that assesses brokers and firms based on the most critical factors including regulation, fees, platform reliability, and real user experiences. We are here to change an unfair system and unlike other review sites that are influenced by partnerships or subjective opinions, CleaRank is 100% independent–abiding by our rigorous CLEAR™ editorial code. We do not accept financial incentives from brokers, so what you see is what you get with no hidden agendas, just honest, actionable feedback. Clear data. Honest reviews. That's the CleaRank promise",
     "numberOfEmployees": {
      "@type": "QuantitativeValue",
      "value": "40"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/09/ew-stock-analysis-2026-09.png",
     "url": "https://clearank.com/wp-content/uploads/2026/09/ew-stock-analysis-2026-09.png",
     "width": "1280",
     "height": "720",
     "caption": "Edwards Lifesciences (EW) stock price analysis chart for September 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/ew-stock-analysis/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/ew-stock-analysis/",
        "name": "Edwards Lifesciences Corporation (EW) Stock Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/ew-stock-analysis/#webpage",
     "url": "https://clearank.com/stock/ew-stock-analysis/",
     "name": "Edwards Lifesciences Corporation (EW) Stock Forecast (2026)",
     "datePublished": "2026-09-04T09:24:46+00:00",
     "dateModified": "2026-09-12T09:45:59+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/09/ew-stock-analysis-2026-09.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/ew-stock-analysis/#breadcrumb"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/writer/clearank/",
     "name": "CleaRank",
     "description": "CleaRank's vision is to bring clarity to the online trading industry and protecting trader interests by delivering data-driven broker evaluations you can trust.",
     "url": "https://clearank.com/writer/clearank/",
     "image": {
      "@type": "ImageObject",
      "@id": "https://secure.gravatar.com/avatar/4900cf75f960a22a21f1c864e98abc4d5285fa159ea1025d0e8a9db5136e28ef?s=96&d=mm&r=g",
      "url": "https://secure.gravatar.com/avatar/4900cf75f960a22a21f1c864e98abc4d5285fa159ea1025d0e8a9db5136e28ef?s=96&d=mm&r=g",
      "caption": "CleaRank",
      "inLanguage": "en-US"
     },
     "sameAs": [
      "https://clearank.com/",
      "https://twitter.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     },
     "logo": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg"
    },
    {
     "@type": "Article",
     "headline": "Edwards Lifesciences Corporation (EW) Stock Forecast (2026)",
     "datePublished": "2026-09-04T09:24:46+00:00",
     "dateModified": "2026-09-12T09:45:59+00:00",
     "author": {
      "@id": "https://clearank.com/writer/clearank/",
      "name": "CleaRank"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "description": "Is Edwards Lifesciences (EW) a Buy or Sell today? Get the AI trade setup, key support levels, valuation and risk analysis. Updated daily.",
     "name": "Edwards Lifesciences Corporation (EW) Stock Forecast (2026)",
     "@id": "https://clearank.com/stock/ew-stock-analysis/#richSnippet",
     "isPartOf": {
      "@id": "https://clearank.com/stock/ew-stock-analysis/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/09/ew-stock-analysis-2026-09.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/ew-stock-analysis/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FinancialProduct",
   "name": "Edwards Lifesciences Corporation (EW)",
   "tickerSymbol": "EW",
   "url": "https://clearank.com/stock/ew-stock-analysis/",
   "description": "AI-powered financial analysis for Edwards Lifesciences Corporation (EW) including technical indicators, market metrics, valuation, and price targets - refreshed daily by CleaRank Financial AI.",
   "exchange": "NYSE",
   "offers": {
    "@type": "Offer",
    "price": 84.37,
    "priceCurrency": "USD",
    "availability": "https://schema.org/InStock",
    "url": "https://clearank.com/stock/ew-stock-analysis/",
    "priceValidUntil": "2026-09-14"
   }
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "Is Edwards Lifesciences Corporation stock a buy right now?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Edwards Lifesciences Corporation (EW) is currently trading at $84.37. While Wall Street analysts have a 'Buy' consensus and a median price target of $101.50, the stock is below its key moving averages and shows moderate insider selling. The high P/E ratio of 51.60 also suggests a premium valuation."
     }
    },
    {
     "@type": "Question",
     "name": "What is the technical outlook for EW stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The technical outlook for EW stock is currently bearish, as it is trading below its 50-day and 200-day SMAs. The RSI is in oversold territory at 24.81, which could signal a potential short-term bounce, but the overall trend indicates weakness."
     }
    },
    {
     "@type": "Question",
     "name": "What are the key risks facing Edwards Lifesciences Corporation?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Key risks include its high valuation relative to sector peers, current bearish technical indicators, and moderate insider selling. The company's earnings performance has also been inconsistent over the past year."
     }
    },
    {
     "@type": "Question",
     "name": "What is the revenue growth forecast for Edwards Lifesciences Corporation?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Revenue growth is projected to be strong, with an estimated 11.00% year-over-year increase for the current year, reaching approximately $6.8 billion, and a further 10.00% growth projected for next year, totaling around $7.4 billion."
     }
    },
    {
     "@type": "Question",
     "name": "How does EW's valuation compare to its sector averages?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Edwards Lifesciences Corporation's P/E ratio of 51.60 is significantly higher than the healthcare sector median of 31.9. Its ROE of 6.9% is also at the sector median, suggesting its valuation is not supported by superior operational efficiency compared to peers."
     }
    },
    {
     "@type": "Question",
     "name": "What is the consensus among Wall Street analysts for EW stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The consensus among 29 Wall Street analysts is 'Buy', with a score of 72 out of 100. The median price target is $101.50, implying an upside of 20.3% from the current price of $84.37."
     }
    },
    {
     "@type": "Question",
     "name": "What does the insider transaction data indicate for EW stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Insider transactions show a 'Net Seller' position, with $34.6 million in total sales and no reported purchases. This 'Moderate Sell Signal' suggests that insiders are reducing their holdings, which can be a cautionary indicator."
     }
    }
   ]
  }
 ]
}